Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review

被引:8
|
作者
Rao, Prakruti S. [1 ]
Modi, Nisha [2 ,3 ]
Nguyen, Nam-Tien Tran [4 ]
Vu, Dinh Hoa [4 ]
Xie, Yingda L. [2 ,3 ]
Gandhi, Monica [5 ]
Gerona, Roy [6 ]
Metcalfe, John [7 ,8 ]
Heysell, Scott K. [1 ]
Alffenaar, Jan-Willem C. [9 ,10 ,11 ]
机构
[1] Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA USA
[2] Rutgers State Univ, Global TB Inst, Newark, NJ USA
[3] Rutgers State Univ, Dept Med, Newark, NJ USA
[4] Hanoi Univ Pharm, Natl Drug Informat & Adverse Drug React Monitorin, Hanoi, Vietnam
[5] Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Maternal Fetal Med Div, San Francisco, CA USA
[7] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA USA
[8] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA USA
[9] Univ Sydney, Pharm Sch, Pharm Bldg A15,Sci Rd, Sydney, NSW 2006, Australia
[10] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[11] Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia
基金
美国国家卫生研究院;
关键词
DRIED BLOOD SPOTS; RESISTANT TUBERCULOSIS; ARKANSAS METHOD; LEVOFLOXACIN PHARMACOKINETICS; ANTITUBERCULOSIS DRUGS; PULMONARY TUBERCULOSIS; ISONIAZID TREATMENT; URINE COLORIMETRY; COLOR TEST; LC-MS/MS;
D O I
10.1007/s40262-023-01220-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveQuantifying exposure to drugs for personalized dose adjustment is of critical importance in patients with tuberculosis who may be at risk of treatment failure or toxicity due to individual variability in pharmacokinetics. Traditionally, serum or plasma samples have been used for drug monitoring, which only poses collection and logistical challenges in high-tuberculosis burden/low-resourced areas. Less invasive and lower cost tests using alternative biomatrices other than serum or plasma may improve the feasibility of therapeutic drug monitoring.MethodsA systematic review was conducted to include studies reporting anti-tuberculosis drug concentration measurements in dried blood spots, urine, saliva, and hair. Reports were screened to include study design, population, analytical methods, relevant pharmacokinetic parameters, and risk of bias.ResultsA total of 75 reports encompassing all four biomatrices were included. Dried blood spots reduced the sample volume requirement and cut shipping costs whereas simpler laboratory methods to test the presence of drug in urine can allow point-of-care testing in high-burden settings. Minimal pre-processing requirements with saliva samples may further increase acceptability for laboratory staff. Multi-analyte panels have been tested in hair with the capacity to test a wide range of drugs and some of their metabolites.ConclusionsReported data were mostly from small-scale studies and alternative biomatrices need to be qualified in large and diverse populations for the demonstration of feasibility in operational settings. High-quality interventional studies will improve the uptake of alternative biomatrices in guidelines and accelerate implementation in programmatic tuberculosis treatment.
引用
收藏
页码:375 / 398
页数:24
相关论文
共 50 条
  • [1] Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review
    Prakruti S. Rao
    Nisha Modi
    Nam-Tien Tran Nguyen
    Dinh Hoa Vu
    Yingda L. Xie
    Monica Gandhi
    Roy Gerona
    John Metcalfe
    Scott K. Heysell
    Jan-Willem C. Alffenaar
    Clinical Pharmacokinetics, 2023, 62 : 375 - 398
  • [2] Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis
    Mota, L.
    Al-Efraij, K.
    Campbell, J. R.
    Cook, V. J.
    Marra, F.
    Johnston, J.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (06) : 819 - 826
  • [3] DAPTOMYCIN: DOES THERAPEUTIC DRUG MONITORING WITH DOSE ADJUSTMENT IMPROVE CLINICAL OUTCOMES?
    Cairns, KA.
    Abbott, IJ.
    Dooley, MJ.
    Peleg, AY.
    Peel, TN.
    Udy, AA.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 31 : S5 - S5
  • [4] Therapeutic drug monitoring in the treatment of tuberculosis
    Peloquin, CA
    DRUGS, 2002, 62 (15) : 2169 - 2183
  • [5] Therapeutic Drug Monitoring in the Treatment of Tuberculosis
    Charles A. Peloquin
    Drugs, 2002, 62 : 2169 - 2183
  • [6] Therapeutic drug monitoring in the treatment of active tuberculosis
    Babalik, Aylin
    Mannix, Sharyn
    Francis, Denis
    Menzies, Dick
    CANADIAN RESPIRATORY JOURNAL, 2011, 18 (04) : 225 - 229
  • [7] Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
    Abdullah Alsultan
    Charles A. Peloquin
    Drugs, 2014, 74 : 839 - 854
  • [8] Therapeutic drug monitoring in the treatment of tuberculosis patients
    Magis-Escurra, Cecile
    van den Boogaard, Jossy
    IJdema, Dirk
    Boeree, Martin
    Aarnoutse, Rob
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2012, 25 (01) : 83 - 86
  • [9] Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
    Alsultan, Abdullah
    Peloquin, Charles A.
    DRUGS, 2014, 74 (08) : 839 - 854
  • [10] Clinical utility of therapeutic drug monitoring of antiepileptic drugs Systematic review
    Al-Roubaie, Zanab
    Guadagno, Elena
    Ramanakumar, Agnihotram V.
    Khan, Afsheen Q.
    Myers, Kenneth A.
    NEUROLOGY-CLINICAL PRACTICE, 2020, 10 (04) : 344 - 355